Literature DB >> 20662054

Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs.

Nicolino Ruperto1, Edward H Giannini, Angela Pistorio, Hermine I Brunner, Alberto Martini, Daniel J Lovell.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20662054     DOI： 10.1002/art.27670

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  15 in total

Review 1.  Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials.

Authors:  Simon Tarp; Gil Amarilyo; Ivan Foeldvari; Robin Christensen; Jennifer M P Woo; Neta Cohen; Tracy D Pope; Daniel E Furst
Journal:  Rheumatology (Oxford)       Date:  2015-11-30       Impact factor: 7.580

2.  Creative trial design in RA: optimizing patient outcomes.

Authors:  Maya H Buch; Sue Pavitt; Mahesh Parmar; Paul Emery
Journal:  Nat Rev Rheumatol       Date:  2013-02-05       Impact factor: 20.543

Review 3.  Heading toward a modern imaging approach in juvenile idiopathic arthritis.

Authors:  Stefano Lanni; Alberto Martini; Clara Malattia
Journal:  Curr Rheumatol Rep       Date:  2014-05       Impact factor: 4.592

Review 4.  Juvenile idiopathic arthritis.

Authors:  Alberto Martini; Daniel J Lovell; Salvatore Albani; Hermine I Brunner; Kimme L Hyrich; Susan D Thompson; Nicolino Ruperto
Journal:  Nat Rev Dis Primers       Date:  2022-01-27       Impact factor: 65.038

Review 5.  Infectious complications in juvenile idiopathic arthritis.

Authors:  Andrew Hurd; Timothy Beukelman
Journal:  Curr Rheumatol Rep       Date:  2013-05       Impact factor: 4.592

6.  Different corticosteroid induction regimens in children and young people with juvenile idiopathic arthritis: the SIRJIA mixed-methods feasibility study.

Authors:  Ashley P Jones; Dannii Clayton; Gloria Nkhoma; Frances C Sherratt; Matthew Peak; Simon R Stones; Louise Roper; Bridget Young; Flora McErlane; Tracy Moitt; Athimalaipet V Ramanan; Helen E Foster; Paula R Williamson; Samundeeswari Deepak; Michael W Beresford; Eileen M Baildam
Journal:  Health Technol Assess       Date:  2020-07       Impact factor: 4.014

7.  Clinical Trial Design in Juvenile Idiopathic Arthritis.

Authors:  Stephen J Balevic; Mara L Becker; Michael Cohen-Wolkowiez; Laura E Schanberg
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.930

8.  Current medical treatments for juvenile idiopathic arthritis.

Authors:  Nicolino Ruperto; Alberto Martini
Journal:  Front Pharmacol       Date:  2011-10-10       Impact factor: 5.810

9.  Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.

Authors:  Hermine I Brunner; Nicolino Ruperto; Zbigniew Zuber; Caroline Keane; Olivier Harari; Andrew Kenwright; Peng Lu; Ruben Cuttica; Vladimir Keltsev; Ricardo M Xavier; Inmaculada Calvo; Irina Nikishina; Nadina Rubio-Pérez; Ekaterina Alexeeva; Vyacheslav Chasnyk; Gerd Horneff; Violetta Opoka-Winiarska; Pierre Quartier; Clovis A Silva; Earl Silverman; Alberto Spindler; Eileen Baildam; M Luz Gámir; Alan Martin; Christoph Rietschel; Daniel Siri; Elzbieta Smolewska; Daniel Lovell; Alberto Martini; Fabrizio De Benedetti
Journal:  Ann Rheum Dis       Date:  2014-05-16       Impact factor: 19.103

10.  Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.

Authors:  Gerd Horneff; Ruben Burgos-Vargas; Tamas Constantin; Ivan Foeldvari; Jelena Vojinovic; Vyacheslav G Chasnyk; Joke Dehoorne; Violeta Panaviene; Gordana Susic; Valda Stanevica; Katarzyna Kobusinska; Zbigniew Zuber; Richard Mouy; Ingrida Rumba-Rozenfelde; Luciana Breda; Pavla Dolezalova; Chantal Job-Deslandre; Nico Wulffraat; Daniel Alvarez; Chuanbo Zang; Joseph Wajdula; Deborah Woodworth; Bonnie Vlahos; Alberto Martini; Nicolino Ruperto
Journal:  Ann Rheum Dis       Date:  2013-05-21       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.